Each testimony, brief or letter is formalized and approved by the our Government Affairs Committee and Board of Directors.
October 17, 2019
BioCT, along with 42 state and regional associations, co-signed a multi-state life sciences association letter to House and Senate Leadership, expressing our strong concerns with recent legislative proposals that threaten to undermine America’s global leadership in biomedical innovation by introducing foreign reference pricing or price controls.
February 4, 2019
Democrats in the Connecticut General Assembly announced joint priorities for the 2019 legislative session. The legislative package focuses on establishing a paid family and medical leave program, raising the minimum wage, investing in job training and the state’s workforce pipeline, supporting small businesses, making prescription drugs more affordable, creating a Green New Deal for Connecticut and increasing access to the ballot box.
January 31, 2019
January 30th, the co-Chairs of the Legislature’s Bioscience Caucus met with their main industry counterpart, BioCT, to discuss the strategic plan developed since the last legislative session, and announce specific goals for the coming session. Alongside co-Chairs State Senator Tony Hwang (R-28), State Senator Christine Cohen (D-12), State Rep. Stephen Harding (R-107), and Rep. Jonathan Steinberg (D-136) was BioCT President & CEO Dawn Hocevar and Dr. Mark Adams, Director of Microbial Genomic Services at Jackson Labs.
February 7, 2018
We are happy to provide you with the 2018 End of Session Report. The Connecticut General Assembly adjourned sine die after making adjustments to close the projected $265 million deficit in fiscal year 2019 in a bipartisan agreement. Additionally, conversations continue as to whether the General Assembly will return for a special session to address sports wagering as a result of the recent Supreme Court case striking down a 26-year federal law that barred all but four states from that practice.
March 9, 2017
For the foregoing reasons, BioCT urges this Committee to progress S.B. No. 960. It is important for the State to conduct the study, particularly if it is to remain competitive in biotechnology. The Bill is therefore in the best interest of the State’s biotechnology and pharmaceutical industries, and for developing new and innovative medicines and therapies for our people.
March 9, 2017
For the foregoing reasons, BioCT urges this Committee to progress S.B. No. 962. It is important to pursue the development of evaluative metrics for bioscience investments in the Connecticut, particularly if it is to remain competitive in biotechnology. The Bill is therefore in the best interest of the State’s biotechnology and pharmaceutical industries, and for developing new and innovative medicines and therapies for our people.
January 23, 2017
The bioscience industry represents a significant share of the State economy and has potential for substantial growth in the coming decade. We hope that the General Assembly will sustain that commitment to growing the bioscience industry through support for research and tax incentives, particularly in view of the current economic climate and the budgetary challenges facing the state.
March 8, 2016
For the foregoing reasons, CURE urges this Committee to progress S.B. No. 313. It is in the best interest of patients, the State’s biotechnology and pharmaceutical industries, and the public at large. The legislation will update Connecticut’s Pharmacy Practice Act to establish a clear substitution process for FDA approved interchangeable biological medicines. Patients here in Connecticut will thereby be provided treatment options, which have already been addressed through legislation in many other states, which would otherwise not be available to them here in this State.
February 24, 2016
For the foregoing reasons, H.B. No. 5270 is not in the best interest of critically ill patients, the State’s thriving biotechnology and pharmaceutical industries, and the public at large. While this legislation is well-intended, it neglects to consider serious challenges associated with providing access to experimental medicines.
Legislative “transparency” initiatives typically describe efforts to give consumers information they can use to make informed decisions. But drug pricing transparency bills are not that kind of legislation. Here, “transparency” refers to the government’s effort to force drug manufacturers to disclose proprietary and competitively sensitive business information in an attempt to coerce companies into restricting the price of their products to artificial, government-set thresholds.
The Biotechnology Innovation Organization (BIO) today launched DrugCostFacts.org, a new interactive web tool designed to help healthcare stakeholders gain a better understanding of the true facts surrounding drug costs, spending and value.
To access archived materials, please send an inquiry to BioCT@bioct.org.